ABC2 Provides Key Funding To Advance Dana-Farber Immunotherapy Research

February 10, 2022

Developing an individualized vaccine relies upon understanding the unique molecular characteristics of a patient’s tumor. In order to do this, Accelerate Brain Cancer Cure is funding the whole exome sequencing of NeoVax tumors at the Broad Institute. This rigorous level of analysis will help Dana-Farber researchers tailor the vaccine to the immunogenic signatures found within the tumor. The following article from Dana-Farber's Insight blog describes the project.

New Immunotherapy Vaccines Show Promise in Treating Brain Tumors

Researchers in Dana-Farber’s Center for Neuro-Oncology are now launching attacks on glioblastomas from a new angle – by turning the patient’s immune system against the cancer cells. Where targeted chemotherapy uses drugs to disable proteins that cancer cells need to grow, immunotherapy drugs stimulate the patient’s immune system to recognize and kill cancer cells.

Traditional drugs and even targeted chemotherapy agents have had little success in treating glioblastoma – the deadliest type of brain tumor.

“Immunotherapy represents a great hope for patients currently facing this disease,” says David Reardon, MD, clinical director of the Center. “We’re anxious to move this approach forward for brain cancer patients.”

Last November, Reardon reported that a new cancer vaccine, rindopepimut, showed promise in a clinical trial of patients whose glioblastoma cells contain a particular gene mutation.

Cancer vaccines are a form of immunotherapy that have been studied and tested for many years with some success. They’re often made from an individual patient’s tumor cells, or parts of them, which are processed in the laboratory and returned to the patient to stimulate a strong immune response.

Click HERE to read the full article in Dana-Farber's Insight blog.